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Fanconi anemia (FA) is a rare inherited disease characterized by developmental defects, short stature, bone marrow failure, and
a high risk of malignancies. FA is heterogeneous: 15 genetic subtypes have been distinguished so far. A clinical diagnosis of FA
needs to be confirmed by testing cells for sensitivity to cross-linking agents in a chromosomal breakage test. As a second step, DNA
testing can be employed to elucidate the genetic subtype of the patient and to identify the familial mutations. This knowledge allows
preimplantation genetic diagnosis (PGD) and enables prenatal DNA testing in future pregnancies. Although simultaneous testing
of all FA genes by next generation sequencing will be possible in the near future, this technique will not be available immediately
for all laboratories. In addition, in populations with strong founder mutations, a limited test using Sanger sequencing and MLPA
will be a cost-eﬀective alternative. We describe a strategy and optimized conditions for the screening of FANCA, FANCB, FANCC,
FANCE, FANCF, and FANCG and present the results obtained in a cohort of 54 patients referred to our diagnostic service since
2008. In addition, the follow up with respect to genetic counseling and carrier screening in the families is discussed.
1. Introduction
Fanconi anemia (FA) is a rare inherited syndrome with
diverse clinical symptoms including developmental defects,
short stature, bone marrow failure, and a high risk of malig-
nancies. Fifteen genetic subtypes have been distinguished:
FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O,
and -P. [1–4]. The majority of patients (∼85%) belong to the
subtypes A (∼60%), C (∼10–15%), or G (∼10%), while a
minority (∼15%) is distributed over the remaining 12 sub-
types, with relative prevalences between <1 and 5%. These
percentages may diﬀer considerably within certain ethnic
groups, due to founder eﬀects. All subtypes seem to fit within
a “classical” FA phenotype, except for D1 and N (mutated in
BRCA2/FANCD1 and PALB2/FANCN), which are associated
with a distinct, more severe, syndromic association. The
mode of inheritance for all subtypes is autosomal recessive,
except for FA-B, which is X-linked. These two diﬀerent
modes of inheritance have important consequences for the
counseling of FA families. The relative prevalence of FA-B
amongst unselected FA patients is estimated at 1.6% [5].
For all genetic subtypes disease genes have been identified
(Table 1). Many mutations found in the various subtypes are
private, but recurrent mutations are known, particularly in
specific ethnic backgrounds (Table 2).
Most FA genes encode orphan proteins with no known
molecular function. At least eight FA proteins (FANCA,
-B, -C, -E, -F, -G, -L, and -M) assemble into a nuclear
multiprotein core complex, which is required to activate
FANCD2 and FANCI by monoubiquitination [6]. FANCL,
which carries a RING finger domain, is supposed to represent
the ubiquitin E3 ligase in this activation [7]. FANCM proba-
bly acts as a sensor of DNA damage and recruits the FA core
complex to the site of damage, but FANCM also interacts
with other proteins including Blm [6]. Monoubiquitination
of FANCD2 and FANCI directs these proteins to areas of
damaged chromatin where they interact with other proteins,
resulting in repair of the damage [6]. The remaining FA
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Table 1: Fanconi anemia complementation groups, genes, and proteins.
Group Gene symbol(s)a Cytogenetic location Protein (amino acids) Domain structure (references)
A FANCA 16q24.3 1455 HEAT repeats [8]
B FANCB Xp22.31 859 —
C FANCC 9q22.3 558 HEAT repeats [8]
D1b BRCA2 13q12.3 3418 RAD51- and DNA-binding motifs [9]
D2 FANCD2 3p25.3 1451 —
E FANCE 6p21.3 536 —
F FANCF 11p15 374 —
G FANCG 9p13 622 Tetratricopeptide repeats (TPR) [10]
I FANCI 15q26.1 1328 —
Jb BRIP1 17q22 1249 DNA helicase [11, 12]
L FANCL 2p16.1 375 RING finger motif (E3 ligase) [7, 8]
M FANCM 14q21.3 2014 DNA helicase, nuclease [13]
Nb PALB2 16p12.1 1186 —
Ob RAD51C 17q25.1 376 —
Pb SLX4 16p13.3 1834 Endonuclease scaﬀold [3, 4]
a
For gene nomenclature see http://www.genenames.org/.
bThe proteins defective in groups D1, J, N, O, and P (boldface) act downstream or independent of the monoubiquitination of FANCD2; all other FA proteins
act upstream of this process.
Table 2: Major recurrent mutations in FA.
Gene Mutation∗
Geographic/ethnic
background
Comment References
FANCA
c.3788 3790del (p.Phe1263del) European, Brazilian Relatively mild [14, 15]
c.1115 1118delTTGG (p.Val372fs) European Relatively mild [16]
Exon 12–17del
Exon 12–31del
South-African
Relatively common in
Afrikaners
[17]
c.295C>T (p.Gln99X)
Spanish Gypsy
population
Worldwide highest
prevalence of mutant
FANCA allele
[18]
FANCC
c.711+4A>T (originally reported as IVS4+4A>T)
Homozygous in 80%
of Ashkenazi Jewish
FA; relatively
common in Japan.
Severe phenotype in Jews,
milder in Japanese.
[19–22]
c.67delG (originally reported as 322delG)
Homozygous in
approx. 50% of Dutch
FA patients
Like other exon 1
mutations, relatively mild
phenotype.
[19, 23–
25]
FANCD2 c.1948-16T>G Turkish Founder mutation [26]
FANCG
c.313G>T (p.Glu105X) European
44% of mutated FANCG
alleles in Germany.
[27]
c.1077-2A>G Portuguese/Brazilian Founder mutation [27, 28]
c.1480+1G>C French-Canadian Founder mutation [28]
c.307+1G>C Japanese Founder mutation [28, 29]
c.1794 1803del (p.Trp599fs) European [28]
c.637 643del (p.Tyr213fs) Sub-Saharan Africa 82% of all black FA patients [30]
FANCJ c.2392C>T (p.Arg798X)
Found in ca. 50% of FA-J
patients of diverse ancestry;
ancient mutation or hot
spot.
[11, 12]
Nucleotide numbering based on ATG = +1.
Published sequence variations in FA genes, with their descriptions conforming to the current nomenclature rules, are listed at http://www.rocke-
feller.edu/fanconi/.
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proteins function downstream of or parallel to the FANCD2
activation step [6]. The exact nature of the DNA damage
response, which when defective causes FA, remains to be
defined. FANCJ/BRIP1 and FANCM possess DNA helicase
motifs, which strongly suggests that the FA pathway acts
through a direct interaction with DNA, presumably to
resolve or remodel blocked DNA replication forks resulting
from DNA interstrand cross-link damage [6]. This idea is
strengthened by the recent extension of the FA pathway with
SLX4, a scaﬀold protein for structure-specific endonucleases
involved in unhooking the DNA cross-link [3, 4].
2. Laboratory Diagnostics in FA
Cells derived from FA patients are—by definition—
hypersensitive to chromosomal breakage induced by DNA
cross-linking agents such as mitomycin C (MMC) or
diepoxybutane (DEB) [31]. This cellular phenotype is
ascertained using stimulated blood T lymphocytes. The
indications for FA laboratory testing are rather broad [32].
As a consequence, in only a small proportion of patients
(about 10%) the chromosomal breakage test is positive,
and an FA diagnosis is established. Since mutation testing
by Sanger sequencing and MLPA is rather laborious, time
consuming and therefore expensive, a positive chromosomal
breakage test is a prerequisite for startingmutation screening.
Confirmation of the FA diagnosis at the DNA level is
important in patients in whom the chromosomal breakage
test was inconclusive. Furthermore, knowledge about the
FA subtype is relevant for the treatment and prognosis
of the patients. In addition, identification of mutations
allows carrier testing in the family and will enable prenatal
DNA testing and preimplantation genetic diagnosis (PGD)
in future pregnancies. Finally, this information can be
used to rule out FA in potential donors for bone marrow
transplantation.
Although simultaneous testing of all FA genes by next
generation sequencing will be possible in the near future,
this technique will not be available immediately for all
laboratories worldwide. In addition, in populations with
strong founder mutations, a limited test using Sanger
sequencing and MLPA will be a cost-eﬀective alternative
[33]. The strategy outlined below has been developed at our
DNA diagnostics laboratory to provide amolecular diagnosis
of FA. It is recognized that mutations in FANCA account
for 60–70% of all FA cases and that about 15–20% of the
mutations in this gene are large deletions [33, 34]. Therefore,
DNA testing usually starts with a screen for deletions in
FANCA. However, depending on the circumstances strategies
may diﬀer from case to case.
2.1. Materials. Genomic DNA (from e.g., leukocytes or
fibroblasts derived from the proband or the parents) is
adequate for most mutation screening assays. Screening
on cDNA is more eﬃcient but has several drawbacks: for
high-quality cDNA, growing cells (stimulated leukocytes,
lymphoblastoid cell lines, or fibroblasts) are necessary. In
addition, common alternative splice variants will hamper
the evaluation of DNA sequences. Therefore, screening on
gDNA is the preferred method for mutation screening.
However, during the diagnostic process, growing cells from
the proband will be helpful in a couple of situations. Growing
cells are indispensable for studying the eﬀect of unclassified
variants on splicing or to verify the disease gene by functional
complementation of the cellular phenotype with a construct
expressing a wild type copy of the suspected gene [35–37].
Finally, if no mutations can be de detected, growing cells can
be used to reconfirm the diagnosis FA by checking MMC
sensitivity in cell growth or G2-arrest assays [38, 39].
2.2. Mutation Screening Strategy
2.2.1. Hints from Ethnic Background or Phenotype. Informa-
tion on the ethnic background of the proband may provide
a clue for a specific pathogenic mutation that most likely
causes the disease, such as c.711 + 4A>T (IVS4 + 4A>T) in
FANCC, a mutation present in homozygous state in 80% of
all FA cases of Ashkenazi Jewish ancestry, and c.295C >T in
FANCA, which was present homozygously in all 40 FA cases
of Spanish Gypsy ancestry so far investigated. More examples
of recurrent mutations are shown in Table 3. The distinct
clinical phenotype of D1 and N patients (severely aﬀected,
often combined with leukemia or solid tumors below the
age of 5 years) may provide a clue to favor BRCA2/FANCD1
and PALB2/FANCN as the first gene to be screened [40–
44]. This is especially worthwhile if confirmed by the cellular
phenotype: in contrast to cells from all other known FA
subtypes, cells from D1, N and O patients are unable to form
RAD51 foci upon exposure to X rays or MMC [43–45].
2.2.2. No Clues Available
(1) In the absence of any clue to the disease gene,
mutation screening starts with a search for deletions
in FANCA, as this type of mutation accounts for
40% of all mutant FANCA alleles. The quantitative
multiplex ligation-dependent probe amplification
(MLPA) method [46] is used for this initial screen,
which identifies FANCA as the most likely disease
gene in 1 out of 4 patients by the detection of a—
usually hemizygous-deletion. In parallel, the FANCA
gene is completely sequenced. The combination of
these two approaches identifies 60–70% of all FA
patients as FA-A.
(2) Next, FANCC, -E, -F, and -G are screened by DNA
sequencing.
(3) Only if the proband is a male, FANCB is screened by
MLPA and DNA sequencing,
In Table 4, optimized conditions are provided for the
PCR amplification of FANCA, -C, -E, -F, -G, and -B. Most
PCRs can be performed under standard conditions. The
PCR primers have M13 extensions which allow sequenc-
ing of all fragments with universal sequencing primers.
MLPA was performed according to the instructions of
the supplier. Detailed information about the sequences of
the MLPA probes is available from the website of the
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Table 3: Mutations detected in a cohort of 54 patients by screening FANCA, FANCC, FANCE, FANCF and FANCG.
Allele 1 Allele 2
Country
of origin1 Gene DNA change Eﬀect
Number of
database entries DNA change Eﬀect
Number of
database entries
1 ES FANCA ex16 17del del 12x c.1115 1118del p.Val372fs 62x
2 PT FANCA c.718C>T p.Gln240X 2x c.2870G>A W957X 1x
3 NL FANCA ex15del del 3x ex15del del 3x
4 NL FANCA c.3788 3790del p.Phe1263del 215x c.3788 3790del p.Phe1263del 215x
5 CA FANCA c.718C>T pGlnx240X 2x c.1085T>C p.Leu362Pro novel
6 PT FANCA c.3788 3790del p.Phe1263del 215x c.4130C>G p.Ser1377X 1x
7 IE FANCA c.2812 2830dup p.Asp944fs 3x c.2812 2830dup p.Asp944fs 3x
8 AU FANCA c.2303T>C p.Leu768Pro 5x c.2303T>C p.Leu768Pro 5x
9 NL FANCA c.862G>T p.Glu288X 1x c.862G>T p.Glu288X 1x
10 NL FANCA ex11 33del del 1x c.2121delC p.Asn707fs novel
11 DK FANCA ex1 8del del 1x c.3788 3790del p.Phe1263del 215x
12 UK FANCA c.337 338del p.Ala114fs 1x c.3349A>G p.Arg1117Gly 2x
13 UK FANCA c.3568C>T p.Gln1190X novel c.3568C>T p.Gln1190X novel
14 NL FANCA c.487delC p.Arg163fs 1x c.2851C>T p.Arg951Trp 11x
15 SE FANCA c.88delG p.Val30fs novel c.100A>T p.Lys34X 2x
16 NL FANCA c.862G>T p.Glu288X 9x c.1771C>T p.Arg591X 9x
17 PT FANCA c.1709 1715+4del p.Glu570fs novel c.3430C>T p.Arg1144Trp novel
18 NO FANCA c.100A>T p.Lys34X 2x c.1378C>T p.Arg460X novel
19 PT FANCA ex15 17del del 2x ex15 17del del 2x
20 NL FANCA c.2982-192A>G splice2 novel ex7 31del del
21 AU FANCA c.427-8 427-5del splice novel c.1771C>T p.Arg591X 9x
22 AU FANCA c.3491C>T p.Pro1164Leu novel c.3491C>T p.Pro1164Leu novel
23 CA FANCA ex4 29del del novel ex31del del 6x
24 NL FANCA c.3391A>G p.Thr1131Ala 15x c.3391A>G p.Thr1131Ala 15x
25 GR FANCA c.2T>C p.Met1? 1x c.3788 3790del p.Phe1263del 215x
26 IE FANCA c.851dup p.Val285fs novel c.2534T>C p.Leu845Pro 4x
27 NL FANCA c.2852G>A p.Arg951Gln 6x c.3624C>T p.= (splice) 2x
28 AU FANCA c.331 334dup p.Leu112fs novel ex22 29del del novel
29 NL FANCA c.862G>T p.Glu288X 9x c.3920delA p.Gln1307fs 2x
30 IR FANCA ex21del del novel ex21del del novel
31 SE FANCA ex1 12del del novel ex22 29del del novel
32 NL FANCB c.755 767del p.Leu252fs novel — — —
33 NL FANCC c.67delG p.Asp23fs 50x c.553C>T p.Arg185X 14x
34 NL FANCC c.67delG p.Asp23fs 50x c.67delG p.Asp23fs 50x
35 CA FANCC c.67delG p.Asp23fs 50x c.553C>T p.Arg185X 14x
36 NL FANCC c.67delG p.Asp23fs 50x c.1155-1G>C splice novel
37 NL FANCC c.67delG p.Asp23fs 50x c.67delG p.Asp23fs 50x
38 NL FANCC c.67delG p.Asp23fs 50x c.467delC p.Ser156fs novel
39 PT FANCE c.1111C>T p.Arg371Trp 6x c.1111C>T p.Arg371Trp 6x
40 UK FANCF c.496C>T p.Gln166X 4x c.496C>T p.Gln166X 4x
41 UK FANCG c.307+2delT splice novel c.307+2delT splice novel
42 UK FANCG c.1471 1473delinsG p.Lys491fs novel c.1471 1473delinsG p.Lys491fs novel
43 NL FANCG c.65G>C p.Arg22Pro 6x c.65G>C; p.Arg22Pro 6x
44 IR FANCG c.307+1G>C splice 21x c.307+1G>C splice 21x
45 NL FANCG c.85-1G>A splice novel c.85-1G>A splice novel
1
Country of origins: AU: Australia; CA: Canada; DK: Denmark; ES: Spain; GR: Greece; IE: Ireland; IR: Iran; NL: Netherlands; PT: Portugal; SE: Sweden; UK:
United Kingdom
Number of database entries refers to the FA database at: http://www.rockefeller.edu/fanconi/.
The pathogenic state of novel missense mutations is based upon in silico prediction algorithms (SIFT, POLYPHEN2, Align GVGD), the presence of a second
clearly pathogenic mutation in the same gene and segregation in the family.
2Eﬀect c.2982-192A>G: by studying cDNA it was shown that the mutation created a new splice donor site resulting in an aberrant mRNA.
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Table 4: Primers and conditions for PCR on genomic DNA of the coding sequence plus intron/exon boundaries of FANCA, FANCC, FANCE,
FANCF, FANCG, and FANCB.
(a)
FANCA
Primer name Sequence (5′ > 3′) Product length (bp)
FANCA ex1F gtaaaacgacggccag GCGCCTCCCCCAGGACCAACA 362
FANCA ex1R caggaaacagctatga AGGCTCTGGCGGGAAGGGATCGG
FANCA ex2F gtaaaacgacggccag CTCTTCGGGAGGGTGTCGCTGGT 328
FANCA ex2R caggaaacagctatga CTCTTCGGGAGGGTGTCGCTGGT
FANCA ex3F gtaaaacgacggccag GCCTGGCCTGGAGCTTGAAT 392
FANCA ex3R caggaaacagctatga CGCAGGTTGAATCAGACGCTGTT
FANCA ex4F gtaaaacgacggccag TAAGGCATTTTAAACAGCAAGTC 430
FANCA ex4R caggaaacagctatga TGCCAATAAATACTGAGCAAACT
FANCA ex5F gtaaaacgacggccag AGTATTGTTTCAGGTAATTTGTT 356
FANCA ex5R caggaaacagctatga TGAAGGTACTTCTTTCCAATCCA
FANCA ex6F gtaaaacgacggccag AGATGTGTTTCAGGCTCTAAGTT 402
FANCA ex6R caggaaacagctatga GCAATGCAATCTAGTCTAGTACA
FANCA ex7F gtaaaacgacggccag TGGGATTTAGTTGAGCCTTACGTCTGC 421
FANCA ex7R caggaaacagctatgaAAGGTGAATGGAAACACTTAAACTCATGTCA
FANCA ex8F gtaaaacgacggccag GTGGTCAGGTGAGCAGTAACTTC 401
FANCA ex8R caggaaacagctatga TAAATAGGTACAAACAGCACGTT
FANCA ex9F gtaaaacgacggccag TTCTCTTGTGTGATGCAGGTATC 332
FANCA ex9R caggaaacagctatga TGACCCACAGATTCATGAGGTAT
FANCA ex10F gtaaaacgacggccag TTTTGATTAAGGCCTACAGATTG 406
FANCA ex10R caggaaacagctatga CCTCCTCCTCACGCACGTTATCG
FANCA ex11F gtaaaacgacggccag TTTCAAGTCTGTGGTTATAGTGG 410
FANCA ex11R caggaaacagctatga AGACGTAAAAGAGGTCCTAGAAT
FANCA ex12F gtaaaacgacggccag CTGTGGGGCTGGTCCTTAACAAA 236
FANCA ex12R caggaaacagctatga AGGCAGCATGACAAGTACTAGGC
FANCA ex13F gtaaaacgacggccag ACATTGGTTTGCTTGGATATTGA 377
FANCA ex13R caggaaacagctatga CTGACAAAGAATGTTCCATCGAC
FANCA ex14F gtaaaacgacggccag TGCTGTAATTGCTGTGTAGTCTT 411
FANCA ex14R caggaaacagctatga ACTCACATGACAGAGAATCAGGT
FANCA ex15F gtaaaacgacggccag ACTACAGCAGCCGCCCGGACACT 430
FANCA ex15R caggaaacagctatga GCAGATCTGCAGGAGGCTCTTGG
FANCA ex16F gtaaaacgacggccag TCCCAGGCAGTTCCCAGACTAAC 312
FANCA ex16R caggaaacagctatga AGCTGATGACAAATCCTCGTAGA
FANCA ex17F gtaaaacgacggccag ACCGCTCCCTCCTCACAGACTAC 334
FANCA ex17R caggaaacagctatga AAGGCTGAAAAACTCAACTCAAG
FANCA ex18F gtaaaacgacggccag GCGCACAGCATGTGGGCCTTTAC 397
FANCA ex18R caggaaacagctatga GCAGCTGCTAGAGGCCTTTTCGG
FANCA ex19F gtaaaacgacggccag GTGCACAAGAAGACTTCATAATG 284
FANCA ex19R caggaaacagctatga AGTCCTTGCTTTCTACACAACTG
FANCA ex20F gtaaaacgacggccag CTTCTCTGTGTTGCAGCATATTC 298
FANCA ex20R caggaaacagctatga AGAAGAAACCTGGAAGTAGTCAT
FANCA ex21F gtaaaacgacggccag ATAATAGATTTGGGGATTGTAAT 255
FANCA ex21R caggaaacagctatga CAACAGACACTCAAGGTTAGGAA
FANCA ex22F gtaaaacgacggccag TGCAGTGAAGAGTCCTGTTGAGT 305
FANCA ex22R caggaaacagctatga ACACACCAGCCTGATGTCACTAT
FANCA ex23F gtaaaacgacggccag CAGTCAGCAGGATCCGTGGAATC 416
6 Anemia
(a) Continued.
FANCA
Primer name Sequence (5′ > 3′) Product length (bp)
FANCA ex23R caggaaacagctatga GGCCCTGGAACATCTGATACGAC
FANCA ex24F gtaaaacgacggccag CCTTCCTGCTGCTCCCGTCC 229
FANCA ex24R caggaaacagctatga CAGACTTGGCCCAGCAAGAG
FANCA ex25F gtaaaacgacggccag CCGCTGGTGGTTGGATTAGCTGT 296
FANCA ex25R caggaaacagctatga TTTCCAGGGCACTGAAGACGAAT
FANCA ex26F gtaaaacgacggccag AGCTTGGAAGAGGGCAGTCTGCT 347
FANCA ex26R caggaaacagctatga CTCTTCTAATTTTATCAAACGAG
FANCA ex27F gtaaaacgacggccag AGACTGTCTCACAACAAACGAAC 356
FANCA ex27R caggaaacagctatga CGGTCCGAAAGCTGCGTAAAC
FANCA ex28F gtaaaacgacggccag GTTGATGGTCTGTTTCCACCTGA 401
FANCA ex28R caggaaacagctatga GAAGGAACGGTCACCTACGTGCT
FANCA ex29F gtaaaacgacggccag GACATGGAGGACTGCGTATGAGA 411
FANCA ex29R caggaaacagctatga GTGGCTGTGATGACTGGAACGTG
FANCA ex30F gtaaaacgacggccag CCCGAGCCGCCAGTCTCAACCCA 411
FANCA ex30R caggaaacagctatga AAAGGCAGACCCACCCTAAGCTA
FANCA ex31F gtaaaacgacggccag GATAAGCCTCCTTGGTCATGGTA 406
FANCA ex31R caggaaacagctatga TGGCAATAAATATCTTAATAGCA
FANCA ex32F gtaaaacgacggccag TTCCTGTGCCAGCATACTGCTCT 359
FANCA ex32R caggaaacagctatga GGGTGGGGACACACAGACAAGTA
FANCA ex33F gtaaaacgacggccag TGGGTTTCAGGGTGGTGGTTGCT 356
FANCA ex33R caggaaacagctatga GAACCCTTTCCTCAGTAATTCAC
FANCA ex34F gtaaaacgacggccag CGCCCAGGGAAGCCGTTAAGTTT 333
FANCA ex34R caggaaacagctatga GCGTTCTGAGAAGGCCACGAGAG
FANCA ex35F gtaaaacgacggccag TTCCTTCACTCTACTAGTTGTGG 311
FANCA ex35R caggaaacagctatga TGAGATGGTAACACCCGTGATGG
FANCA ex36F gtaaaacgacggccag CCATCTCAGCCACCCTCATCTGT 350
FANCA ex36R caggaaacagctatga AGGCGCCCACCACCACGAGAACT
FANCA ex37F gtaaaacgacggccag GACTTGGTTTCTATGGCGTGGTT 310
FANCA ex37R caggaaacagctatga CCCAGAGAAATAGCACTGATTGA
FANCA ex38F gtaaaacgacggccag GTTTTCTAAGATCCACTTAAAGG 362
FANCA ex38R caggaaacagctatga CTCACTCACACTTCCGCAAACAC
FANCA ex39F gtaaaacgacggccag CTGTCCAGAGGCCCAGTATTACC 387
FANCA ex39R caggaaacagctatga AGGAGGGCTCGTTCTTAACCATT
FANCA ex40F gtaaaacgacggccag GGTGTCCCCAGCACTGATAATAG 353
FANCA ex40R caggaaacagctatga AGACATAGTGACAAATGGCTACA
FANCA ex41F gtaaaacgacggccag CCCTTGGCATCACCTGCTACCTT 403
FANCA ex41R caggaaacagctatga AACAGGCAAACTCACAGGTTAGA
FANCA ex42F gtaaaacgacggccag ACCAGCCCTGTTTCTGTATGTCT 248
FANCA ex42R caggaaacagctatga ACATGGCCCAGGCAGCTGTCAAT
FANCA ex43F gtaaaacgacggccag TGTGGGGGACATGAGAATTGACA 378
FANCA ex43R caggaaacagctatga GTAATCCACTTTTTAGTGCAACA
FANCAIVS10F gtaaaacgacggccag TTTACATGTGCATCAGTTAGCTT 184
FANCAIVS10R caggaaacagctatga CATGAAGACACAGAAAAAGTAGGT
(b)
FANCC
Primer name Sequence (5′ > 3′) Product length (bp)
FANCC ex1F
FANCC ex1R
gtaaaacgacggccag ACCATTTCCTTCAGTGCTGGACA
caggaaacagctatga CCATCGGCACTTCAGTCAATACC
378
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(b) Continued.
FANCC
Primer name Sequence (5′ > 3′) Product length (bp)
FANCC ex2F
FANCC ex2R
gtaaaacgacggccag CTAAACAAGAAGCATTCACGTTC
caggaaacagctatga GGAGAAAGGTTCATAATGTAAGC
303
FANCC ex3F
FANCC ex3R
gtaaaacgacggccag TCAGCAGAAAGAGAATGTGCAAA
caggaaacagctatga AACATCATAGAACTGGATTCCAC
405
FANCC ex4F
FANCC ex4R
gtaaaacgacggccag TGTACATAAAAGGCACTTGCATT
caggaaacagctatga TCCCATCTCACATTTCTTCCGTA
380
FANCC ex5F
FANCC ex5R
gtaaaacgacggccag AGAACTGATGTAATCCTGTTTGC
caggaaacagctatga TTACTGCTCTGTGAGAGTTGAGA
367
FANCC ex6F
FANCC ex6R
gtaaaacgacggccag GTCTTTGACCTTTTTAGCATGAA
caggaaacagctatga AACGTTTGGACACTGCTGTCGTA
387
FANCC ex7F
FANCC ex7R
gtaaaacgacggccag ATTAGTGATTGCATTTTGAACTT
caggaaacagctatga CAAAAATAAAATGTAAATACACG
422
FANCC ex8F
FANCC ex8R
gtaaaacgacggccag CTCCTTTGGCTGATAATAGCAAG
caggaaacagctatga CTGATTTTTGAGTTTTTACCTCT
336
FANCC ex9F
FANCC ex9R
gtaaaacgacggccag ATACTGCTGAAGCTTATGGCACA
caggaaacagctatga TAACCTTTGTTGGGGCACTCATT
400
FANCC ex10F
FANCC ex10R
gtaaaacgacggccag TATGAGGTTATTGGGAGCTTATT
caggaaacagctatga CTGTCTCCCTCATGCTGTAGATA
382
FANCC ex11F
FANCC ex11R
gtaaaacgacggccag GAACCAGAAGTAAAGGGCGTCTC
caggaaacagctatga CTGACCTGCTCCAAGCCATCCGT
416
FANCC ex12F
FANCC ex12R
gtaaaacgacggccag AAGTACAATTTAAGCCAACCGTT
caggaaacagctatga AGGTTGCCATGACATATGCCATC
451
FANCC ex13F
FANCC ex13R
gtaaaacgacggccag CCTCTCTCAGGGGCCAGTGCTTA
caggaaacagctatga AGACCCTCGGACAGGTAACCCAC
435
FANCC ex14F
FANCC ex14R
gtaaaacgacggccag ACTTGCTATGCTAATCACCTTGC
caggaaacagctatga AATGCGTGGCCACAGGTCATCAC
437
(c)
FANCE
Primer name Sequence (5′ > 3′) Product length (bp)
FANCE ex1F
FANCE ex1R
gtaaaacgacggccag CGCCTCCCTCCTTCCCTTTC
caggaaacagctatga CCCGCCTCCCATACCTGCTAA
540
FANCE ex2aF
FANCE ex2aR
gtaaaacgacggccag GCTCTGCCCAGTCTGCCTTGTGC
caggaaacagctatga CTCTGAGTCCTTTCTGCGTTTCC
469
FANCE ex2bF
FANCE ex2bR
gtaaaacgacggccag GCCAGAGACAGCTCCAAAGTCTA
caggaaacagctatga CAGCCTTCCCCATGGATAAAGCC
479
FANCE ex3F
FANCE ex3R
gtaaaacgacggccag GCCTCTTGACTTTCTTGAATCAT
caggaaacagctatga ACTGTCCTCAGACCTTTACTCCA
352
FANCE ex4F
FANCE ex4R
gtaaaacgacggccag TTGAACCAAGTGTAGACTTACCA
caggaaacagctatga GGGAAGGAACCAAGGGCTAAAAG
436
FANCE ex5F
FANCE ex5R
gtaaaacgacggccag GTATCTTTTAGCCCTTGGTTCCT
caggaaacagctatga GAATCCCCTCTCTCAAGTACCAC
431
FANCE ex6F
FANCE ex6R
gtaaaacgacggccag TTTCCTTTGTAACATGTATCATC
caggaaacagctatga AGCAGAAAGCAGGGAGGCGGTAA
433
FANCE ex7F
FANCE ex7R
gtaaaacgacggccag ACAGGCTGGGCATTCTGTTACCG
caggaaacagctatga AGTGAGACACAAGGATCCCCTAA
425
FANCE ex8F
FANCE ex8R
gtaaaacgacggccag TTGGAGCAGCAGATAGATACTCA
caggaaacagctatga AGAGGTGGAGCTGAAGTGACCAT
380
FANCE ex9F
FANCE ex9R
gtaaaacgacggccag GTTACCTGCCCAGGGTCACCTAG
caggaaacagctatga CTGGCCAGCACTCAGGGTTTTAT
388
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(c) Continued.
FANCE
Primer name Sequence (5′ > 3′) Product length (bp)
FANCE ex10F
FANCE ex10R
gtaaaacgacggccag TGGCCTCCTCTCTCCTCAATAGA
caggaaacagctatga AACAGGGAGGCAGTTGCAATCTG
369
(d)
FANCF
Primer name Sequence (5′ > 3′) Product length (bp)
FANCF ex1aF
FANCF ex1aR
gtaaaacgacggccag TTTCGCGGATGTTCCAATCAGTA
caggaaacagctatga CTGCACCAGGTGGTAACGAGCTG
449
FANCF ex1bF
FANCF ex1bR
gtaaaacgacggccag AGTGGAGGCAAGAGGGCGGCTTT
caggaaacagctatga GCTATCACCTTCAGGAAGTTGTT
456
FANCF ex1cF
FANCF ex1cR
gtaaaacgacggccag CCCAAATCTCCAGGAGGACTCTC
caggaaacagctatga TTTCTGAAGGTCATAGTGCAAAC
444
FANCF ex1dF
FANCF ex1dR
gtaaaacgacggccag GCTTTTGACTTTAGTGACTAGCC
caggaaacagctatga ATTTGGTGAGAACATTGTAATTT
456
(e)
FANCG
Primer name Sequence (5′ > 3′) Product length (bp)
FANCG ex1F
FANCG ex1R
gtaaaacgacggccag AGCCTGGGCGGGTGGATTGGGAC
caggaaacagctatga TCATTTCTGGCTCTTTGGTCAAG
389
FANCG ex2F
FANCG ex2R
gtaaaacgacggccag CAGGCCAAGGTAACACGGTTGCT
caggaaacagctatga CCAGTCTCCTCTGTGCCTTAAAC
460
FANCG ex3F
FANCG ex3R
gtaaaacgacggccag TATTGTAGCTGTTTTGGTTGGAG
caggaaacagctatga GGTGACAGATGTTGTTTATCCTC
362
FANCG ex4F
FANCG ex4R
gtaaaacgacggccag GGAGATGGAGGATGAGGTGCTAC
caggaaacagctatga CGACCACCAACCCAGCCGCCTGT
411
FANCG ex5F
FANCG ex5R
gtaaaacgacggccag AGATGGAGATAGGAGAAGACGAG
caggaaacagctatga GCTTCATGAAGGCTGCTTAGTGC
454
FANCG ex6F
FANCG ex6R
gtaaaacgacggccag CAGTTCCATGGGCTTCTTAGACC
caggaaacagctatga TCAGGGCTGCAACCAAGTACAAC
393
FANCG ex7F
FANCG ex7R
gtaaaacgacggccag GCACTGGGGTCCTGTCACCGTAA
caggaaacagctatga ATAATCTTTGGGAGCCATACTTC
418
FANCG ex8F
FANCG ex8R
gtaaaacgacggccag GCTTGTGATGGGGTGACTTGACT
caggaaacagctatga AGTTCAGGTCTAGAAGCAAGGTA
438
FANCG ex9F
FANCG ex9R
gtaaaacgacggccag CCTCCTCAGGGCCCATGAACATC
caggaaacagctatga GCAGTGTCTTGAAAGGCATGAGC
400
FANCG ex10F
FANCG ex10R
gtaaaacgacggccag CAGGACTCTGCATGGTACCAG
caggaaacagctatga CCAATCAGAAAATCATCCCTC
460
FANCG ex11F
FANCG ex11R
gtaaaacgacggccag AGCTCCATGTTCACCTACTTACC
caggaaacagctatga CAGTGCCGCATCTGACTTACATC
397
FANCG ex12F
FANCG ex12R
gtaaaacgacggccag AGGATTTGGGGTTTTGGTGACTG
caggaaacagctatga AACTCTTGGGAGCCCTGCATACA
445
FANCG ex13F
FANCG ex13R
gtaaaacgacggccag CCGCTTCCATATGTGAGTGTAGG
caggaaacagctatgaC CACAATAGGTCCAAGGACTCTA
340
FANCG ex14F
FANCG ex14R
gtaaaacgacggccag CCAAACTAAGGGGTCACATGAAG
caggaaacagctatga GATGGTGAAGCAGAAAGCCCTCC
405
(f)
FANCB
Primer name Sequence (5′ > 3′) Product length (bp)
FANCB ex3AF
FANCB ex3AR
gtaaaacgacggccag
GATATGGTTATTTGAATTCTTAGCAcaggaaacagctatga
GCCATCCTTCATCTCATAGCCTAGT
721
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(f) Continued.
FANCB
Primer name Sequence (5′ > 3′) Product length (bp)
FANCB ex3BF
FANCB ex3BR
gtaaaacgacggccag
ATTAACCTCCCTTACATTGTGATAGcaggaaacagctatga
CAATAAGACTCCAGAATGAACTCTA
811
FANCB ex4F
FANCB ex4R
gtaaaacgacggccag
TTTACAAATGACAACTACATGAcaggaaacagctatga
TTAAGTATAAAACCACCAATAT
391
FANCB ex5F
FANCB ex5R
gtaaaacgacggccag ACTGCATCTGGCCTATAGTTcaggaaacagctatga
AATACCATTTTTACCCAAGC
411
FANCB ex6F
FANCB ex6R
gtaaaacgacggccag GTATTTCCTGAATTATTGGTATGTC
caggaaacagctatga CATAAAAGTCCACCATTATAACCTC
395
FANCB ex7F
FANCB ex7R
gtaaaacgacggccag TGTTTGGGCCATAAGCCCTA
caggaaacagctatga TTCTGGAGCATCAAGACAGT
355
FANCB ex8F
FANCB ex8R
gtaaaacgacggccag GTTGTTTGTATGACATTTAATCATC
caggaaacagctatga ATCATTAAACTCTGCCCATTATCAG
636
FANCB ex9F
FANCB ex9R
gtaaaacgacggccag AGGTAATTTTGTTGGCACTT
caggaaacagctatga ATGCGTTCATTCATGCTAGG
531
FANCB ex10F
FANCB ex10R
gtaaaacgacggccag AATTGGTTCTGTTTATCATTATGGT
caggaaacagctatga CTACTACAGTAAGCCTCGGTGTTTA
686
PCR conditions:
PCR was performed in Applied Biosystems PE9700 system using 96-well plates. PCR reactions (final volume 25 µl) contained 0.5 units Platinum Taq
polymerase (Invitrogen), 1,5mM MgCl2, 0.2mM NTPs (Invitrogen), and 10 pmol primer.
For the large majority of amplicons, standard PCR conditions were used: preheat 95◦C, 5min, denaturation 95◦C, 30 sec, annealing 60◦C, 30 sec., elongation
72◦C, 1min, number of cycles: 33.
Fragments with a diﬀerent annealing temperature were FANCA exons 5, 7, 13, 21, 26, 31, and 38, FANCC exon 7, FANCF fragment 1d and FANCE exon
1 : 55◦C; FANCA exon 1 : 64◦C. For FANCE exon 1 the PCR mix was supplemented with 10% DMSO.
For FANCB diﬀerent PCR conditions were used: preheat 95◦C, 5min, denaturation 95◦C, 1min, annealing 50◦C, 1min., elongation 72◦C, 1min., number
of cycles 30. For FANCB exon 7 and 9 the annealing temperature was 55◦C. For sequencing of exon 7 forward, a special sequencing primer was used: 5′-
TTTTTAGAAGGAATGTCTTG-3′.
FA gene specific part of the primer is indicated in capitals. Primers are extended with M13 sequence (indicated in normal letter type), which is used for the
sequencing reaction.
supplier (www.mlpa.com). In a well-equipped laboratory
with suﬃcient dedicated personal, testing of FANCA, -C, -E,
-F, -G and -B can be completed within 1-2 weeks.
After screening FANCA, -C, -E, -F, -G, and –B, a molecu-
lar diagnosis is obtained for∼85% of the patients [34]. In our
cohort of 54 patients, referred to our diagnostic service since
2008, mutations were detected in 45 patients (83%). FANCA
mutations were found in 31 of the patients (57%), FANCC
mutations in 6 patients (11%), and FANCG mutations in
5 patients (9%). FANCB, FANCE, and FANCF mutations
were found in single families (Table 3). In the small group
of patients without mutations no complementation analysis
or FANCD2 western blotting was performed. Therefore,
we do not know if we missed FANCA, -C, -E, -F, -G,
and -B mutations in these patients or that these patients
have mutations in other FA genes. Table 3 does not include
prenatal cases, because prenatal testing is only oﬀered in
couples in which the FA-causing mutations are already
established. Testing was oﬀered as a diagnostic service for
which a fee was charged.
For the patients negative for FANCA, -C, -E, -F, -G, and
-B mutations, next generation sequencing can be used to
analyze all other FA genes. If this technique is not available,
further analysis will depend on the availability of growing
cells from the proband. In that case a western blot should
reveal whether both FANCD2 isoforms are present at normal
levels.
(1) If both FANCD2 bands are absent or very weak,
FANCD2 is sequenced. Because of the presence of
FANCD2 pseudogene sequences in the genome, this
testing must be performed on cDNA or gDNA using
specially designed primers [26].
(2) If only the short isoform of FANCD2 is present,
FANCL and FANCM are sequenced. If no mutations
are found, the patient may be mutated in FANCI or
in another unidentified FA gene acting upstream of
FANCD2.
(3) If both isoforms are present, and if the clinical
phenotype is compatible with FA-D1 or FA-N,
BRCA2/FANCD1 and PALB2/FANCN are screened
by MLPA and DNA sequencing.
(4) If negative, BRIP1/FANCJ, PALB2/FANCN, RAD51C/
FANCO, and SLX4/FANCP are sequenced.
(5) If negative again, the patient should be screened
for mutations in NBS1, ESCO2 and DDX11 to
test for Nijmegen breakage syndrome, Roberts syn-
drome and Warsaw Breakage syndrome, respectively
[47, 48]. The latter two syndromes can also be
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excluded by analyzing metaphase spreads for sister
chromatid cohesion defects. If again negative, the
patient is likely to be mutated in a novel FA gene
acting downstream of FANCD2 ubiquitination.
3. Notes
3.1. Mutation Screening in Mosaic Patients. If an available
lymphoblastoid cell line from an FA patient is phenotypically
normal due to genetic reversion at the disease locus,
mutation screening is still possible in the reverted cell line,
since at least one mutation will be present [49–51]. The
second mutation may be identified through investigating the
parents.
3.2. Unclassified Variants. Missense mutations or in-frame
deletions or insertions should be judged using in silico
prediction algorithms (SIFT, POLYPHEN2, Align GVGD).
Alternatively, they can be tested for pathogenicity in a cellular
transfection assay to check the ability of the variant gene
product to complement the cellular FA defect in a deficient
cell line (see e.g., [10, 35, 52]). Generally, these tests are only
feasible in a setting where a diagnostic laboratory is equipped
with a research laboratory with all necessary technology.
3.3. Functional Assignment to Genetic Subtypes. Retroviral
constructs have been used to identify the FA subtype by
functional complementation, as an intermediate step before
a mutation screen is undertaken [36]. Although knowing
the disease gene facilitates mutation screening, retroviral
transduction has some drawbacks in comparison to direct
mutation screening: (i) growing, MMC-sensitive cells either
from a cell line or fresh blood sample are required, which
are not always easy to obtain; (ii) overexpression of some
FA proteins (e.g., FANCM and FANCP) may be toxic
for cells; (iii) novel genetic subtypes that emerge after all
known groups have been excluded and cannot be readily
distinguished from false negatives, that is, transductions that
for some unknown reason have failed to cause complementa-
tion; (iv) the method requires relatively advanced laboratory
facilities and technology. However, functional assignment
of complementation group can rapidly be provided by
laboratories with capability for this type of analysis [37],
which has greatly facilitated reliable genotyping for over 95%
of FA patients for which viral constructs are available.
3.4. Genetic Counseling. All patients with a diagnosis of
FA confirmed by mutation analysis should be referred for
genetic counselling, together with their parents and siblings.
Mutation testing should be performed in all sibs regardless
of any clinical symptoms. A complete pedigree, including
a cancer history anamnesis, should be prepared. Mutation
carriers might be at increased cancer risk (see Section 3.7)
whose aspect should be included in the counseling (see
Section 3.7).
FA patients themselves usually have decreased fertility.
Women usually have late menarche, irregular menses, and
early menopause. However, pregnancies in women with
FA have been described, and therefore women should be
adequately informed about the risks for their oﬀspring,
which is mainly related to an increase in pregnancy-related
complications [53].
Sibs of the parents of an FA patient often request carrier
screening to assess their risk of getting a child with FA. If a
sib appears to be carrier, this risk is still minimal because
of the very low carrier frequency in the population. In the
US the carrier frequency has been estimated to be about 1 in
181 [54]. The risk of a proven carrier to get a child with FA
is therefore about 1 in 724. However, in small communities
or in consanguineous couples this risk is much higher, and
mutation screening in spouses of proven carriers may be
indicated.
3.5. Prenatal Diagnosis. Prenatal diagnosis of FA is relatively
straightforward after the pathogenic mutations in a given
family have been identified. Fetal cells can be obtained by
chorionic villus sampling (CVS) during weeks 10–12 of the
pregnancy or by amniocentesis, which is performed between
weeks 14 and 16. However, CVS may be preferred as the
diagnosis will be known at an earlier stage. If the mutation
is not known, a chromosomal breakage test on fetal material
may be performed [55], but this test may be considered less
reliable than screening for mutations in the fetal material.
Alternatively, flow cytometric testing of MMC sensitivity
in amniotic cell cultures might be an option; however this
technique is only available in a limited number of specialized
laboratories [56]. Occasionally, FA may be suspected by fetal
ultrasound imaging and confirmed by parental carrier testing
when the family is not yet known to carry a risk for FA [57].
3.6. Genotype-Phenotype Correlation. FA is considered as one
disease, and the question may be raised whether all fifteen
genetic subtypes equally conform to the clinical FA phe-
notype. Genotype-phenotype correlation studies comparing
the 3 most common groups A, C, and G indicated modest
phenotypic diﬀerences, which were rather correlated with the
relative severity of the mutations [23]. However, bias due
to the ethnic distribution of the studied population is very
well possible. Other studies reported significant diﬀerences
between FA-A/G versus FA-C [58]. Cases in group FA-
D1 (mutated in BRCA2) and FA-N (mutated in PALB2)
present with a distinct, relatively severe, phenotype that is
characterized by the development of leukemia at very young
age (median 2.2 years) and by pediatric cancers such as
nephroblastoma (Wilms tumor) or medulloblastoma [40–
44]. The observations that one of the pathogenic mutations
in BRCA2 in FA-D1 patients is hypomorphic and that mice
with biallelic null alleles in Brca2 are embryonic lethals
suggest that the BRCA2 protein serves a function that is
essential for survival.
Diﬀerent mutations in the same gene may be associated
with divergent phenotypes, as illustrated by the two FANCC
mutations, c.711+4A>T and c.67delG. The former (splice-
site) mutation is associated with a relatively severe phenotype
in Ashkenazi Jewish people [19] although the associated
phenotype was reportedly less severe in patients of Japanese
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ancestry [20]. The carrier frequency for this mutation in
the Ashkenazi population is relatively high (1 in 87), which
has led to the recommendation of carrier detection to
prevent disease [59]. In the Netherlands more than 50%
of FA cases are homozygous for the FANCC frameshift
mutation c.67delG. The phenotype associated with this
mutation, like other exon 1 mutations, seems relatively
mild, as these patients rarely have skeletal abnormalities and
show a relatively late age of onset of their marrow failure
[24]. Awareness of such genetically determined phenotypic
diﬀerences may help in clinical decision making, including
the counselling of patients and families.
3.7. Cancer Risk in Heterozygous Mutation Carriers. An
important issue is whether FA mutation carriers are at
increased risk to develop cancer or other types of disease.
Overall, there is no increased risk for cancer among FA
heterozygotes [60, 61]. However, the situation is diﬀerent in
some of the less prevalent FA subtypes. The FA-D1 subtype
is caused by mutations in BRCA2 [62] which is a well-known
breast and ovarian cancer predisposition gene [63]. In FA-D1
one of the mutations will be hypomorphic because biallelic
“severe” mutations are supposed to be lethal [26]. Therefore,
one of the parents of a FA-D1 patient will be a heterozygous
carrier of a “severe” inactivating BRCA2 mutation and may
thus have an increased risk for breast cancer and other
BRCA2-associated cancers. Whether the parent with the
hypomorphic mutation is also at increased risk is unknown:
in breast cancer families these hypomorphic mutations are
considered as variants with unknown clinical significance.
Two other genes involved in FA and related to breast or
ovarian cancer predisposition are PALB2/FANCN [64, 65]
and RAD51C/FANCO [66]. Although cancer patients have
been identified with germ-line mutations in these genes, an
accurate estimate of the relative cancer risk for mutation
carriers is still lacking.
Another special case is represented by female FANCB
mutation carriers, who are supposed to consist of 50%
FA-like cells due to silenced expression of the wild type
FANCB allele by the random process of X inactivation that
occurs during early embryonic development. Nevertheless,
in the few female FANCB mutation carriers studied so far,
inactivation appeared strongly skewed towards the mutated
allele [67]. This suggests that FA cells have a poor chance
to survive next to unaﬀected cells in the same tissue, and
these FA cells may therefore not give an increased cancer
risk. However, the data are scarce at present so that no firm
conclusions can be drawn regarding the cancer risk of female
FANCB mutation carriers [60].
Conflict of Interests
The authors do not declare any conflict of interests related to
this study.
Acknowledgments
The authors thank the Fanconi Anemia Research Fund, Inc.,
Eugene, OR, the Netherlands Organization for Health and
Development, and the Dutch Cancer Society, for financial
support.
References
[1] J. P. deWinter and H. Joenje, “The genetic andmolecular basis
of Fanconi anemia,” Mutation Research, vol. 668, no. 1-2, pp.
11–19, 2009.
[2] F. Vaz, H. Hanenberg, B. Schuster et al., “Mutation of the
RAD51C gene in a Fanconi anemia-like disorder,” Nature
Genetics, vol. 42, no. 5, pp. 406–409, 2010.
[3] C. Stoepker, K. Hain, B. Schuster et al., “SLX4, a coordinator of
structure-specific endonucleases, is mutated in a new Fanconi
anemia subtype,” Nature Genetics, vol. 43, no. 2, pp. 138–141,
2011.
[4] Y. Kim, F. P. Lach, R. Desetty, H. Hanenberg, A. D. Auerbach,
and A. Smogorzewska, “Mutations of the SLX4 gene in
Fanconi anemia,” Nature Genetics, vol. 43, no. 2, pp. 142–146,
2011.
[5] M. Levitus, H. Joenje, and J. P. de Winter, “The Fanconi
anemia pathway of genomic maintenance,” Cellular Oncology,
vol. 28, no. 1-2, pp. 3–29, 2006.
[6] A. J. Deans and S. C. West, “DNA interstrand crosslink repair
and cancer,” Nature Reviews Cancer, vol. 11, no. 7, pp. 467–
480, 2011.
[7] A. R. Meetei, J. P. de Winter, A. L. Medhurst et al., “A
novel ubiquitin ligase is deficient in Fanconi anemia,” Nature
Genetics, vol. 35, no. 2, pp. 165–170, 2003.
[8] E. Blom, “Evolutionary clues to the molecular function of
Fanconi anemia genes,” in Thesis, VU University Medical
Center, Amsterdam, The Netherlands, 2006.
[9] S. C. West, “Molecular views of recombination proteins and
their control,” Nature Reviews Molecular Cell Biology, vol. 4,
no. 6, pp. 435–445, 2003.
[10] E. Blom, H. J. van de Vrugt, Y. de Vries, J. P. de Winter, F.
Arwert, and H. Joenje, “Multiple TPR motifs characterize the
Fanconi anemia FANCG protein,” DNA Repair, vol. 3, no. 1,
pp. 77–84, 2004.
[11] M. Levitus, Q. Waisfisz, B. C. Godthelp et al., “The DNA heli-
case BRIP1 is defective in Fanconi anemia complementation
group J,” Nature Genetics, vol. 37, no. 9, pp. 934–935, 2005.
[12] O. Levran, C. Attwooll, R. T. Henry et al., “The BRCA1-
interacting helicase BRIP1 is deficient in Fanconi anemia,”
Nature Genetics, vol. 37, no. 9, pp. 931–933, 2005.
[13] A. R.Meetei, A. L. Medhurst, C. Ling et al., “A human ortholog
of archaeal DNA repair protein Hef is defective in Fanconi
anemia complementation group M,” Nature Genetics, vol. 37,
no. 9, pp. 958–963, 2005.
[14] O. Levran, T. Erlich, N. Magdalena et al., “Sequence variation
in the Fanconi anemia gene FAA,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 94, no.
24, pp. 13051–13056, 1997.
[15] N. Magdalena, D. V. Pilonetto, M. A. Bitencourt et al.,
“Frequency of Fanconi anemia in Brazil and eﬃcacy of
screening for the FANCA 3788-3790del mutation,” Brazilian
Journal of Medical and Biological Research, vol. 38, no. 5, pp.
669–673, 2005.
[16] O. Levran, R. Diotti, K. Pujara, S. D. Batish, H. Hanenberg,
and A. D. Auerbach, “Spectrum of sequence variations in
the FANCA gene: an International Fanconi Anemia Registry
(IFAR) study,” Human Mutation, vol. 25, no. 2, pp. 142–149,
2005.
[17] A. J. Tipping, T. Pearson, N. V. Morgan et al., “Molecular
and genealogical evidence for a founder eﬀect in Fanconi
12 Anemia
anemia families of the Afrikaner population of South Africa,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 98, no. 10, pp. 5734–5739, 2001.
[18] E. Callen, J. A. Casado, M. D. Tischkowitz et al., “A common
founder mutation in FANCA underlies the world’s highest
prevalence of Fanconi anemia in Gypsy families from Spain,”
Blood, vol. 105, no. 5, pp. 1946–1949, 2005.
[19] A. P. Gillio, P. C. Verlander, S. D. Batish, P. F. Giampietro,
and A. D. Auerbach, “Phenotypic consequences of mutations
in the Fanconi anemia FAC gene: an international Fanconi
anemia registry study,” Blood, vol. 90, no. 1, pp. 105–110, 1997.
[20] M. Futaki, T. Yamashita, H. Yagasaki et al., “The IVS4 + 4A to T
mutation of the Fanconi anemia gene FANCC is not associated
with a severe phenotype in Japanese patients,” Blood, vol. 95,
no. 4, pp. 1493–1498, 2000.
[21] M. A. Whitney, H. Saito, P. M. Jakobs, R. A. Gibson, R. E.
Moses, and M. Grompe, “A common mutation in the FACC
gene causes Fanconi anaemia in Ashkenazi Jews,” Nature
Genetics, vol. 4, no. 2, pp. 202–205, 1993.
[22] D. Kutler and A. Auerbach, “Fanconi anemia in Ashkenazi
Jews,” Familial Cancer, vol. 3, no. 3-4, pp. 241–248, 2004.
[23] L. Faivre, P. Guardiola, C. Lewis et al., “Association of
complementation group and mutation type with clinical
outcome in Fanconi anemia,” Blood, vol. 96, no. 13, pp. 4064–
4070, 2000.
[24] T. Yamashita, N. Wu, G. Kupfer et al., “Clinical variability of
Fanconi anemia (type C) results from expression of an amino
terminal truncated Fanconi anemia complementation group
C polypeptide with partial activity,” Blood, vol. 87, no. 10, pp.
4424–4432, 1996.
[25] H. Joenje, “Fanconi anaemia complementation groups in
Germany and the Netherlands,” Human Genetics, vol. 97, no.
3, pp. 280–282, 1996.
[26] R. Kalb, K. Neveling, H. Hoehn et al., “Hypomorphic
mutations in the gene encoding a key Fanconi anemia protein,
FANCD2, sustain a significant group of FA-D2 patients with
severe phenotype,” American Journal of Human Genetics, vol.
80, no. 5, pp. 895–910, 2007.
[27] I. Demuth, M. Wlodarski, A. J. Tipping et al., “Spec-
trum of mutations in the Fanconi anaemia group G gene,
FANCG/XRCC9,” European Journal of Human Genetics, vol. 8,
no. 11, pp. 861–868, 2000.
[28] A. D. Auerbach, J. Greenbaum, K. Pujara et al., “Spectrum
of sequence variation in the FANCG gene: an International
Fanconi Anemia Registry (IFAR) study,” Human Mutation,
vol. 21, no. 2, pp. 158–168, 2003.
[29] H. Yagasaki, T. Oda, D. Adachi et al., “Two common
founder mutations of the fanconi anemia group G gene
FANCG/XRCC9 in the Japanese population,” Human muta-
tion, vol. 21, no. 5, p. 555, 2003.
[30] N. V. Morgan, F. Essop, I. Demuth et al., “A common Fanconi
anemia mutation in black populations of sub-Saharan Africa,”
Blood, vol. 105, no. 9, pp. 3542–3544, 2005.
[31] J. Rosendorﬀ and R. Bernstein, “Fanconi’s anemia—
chromosome breakage studies in homozygotes and
heterozygotes,” Cancer Genetics and Cytogenetics, vol. 33,
no. 2, pp. 175–183, 1988.
[32] B. P. Alter, “Diagnostic evaluation of FA,” in Fanconi Anemia:
Guidelines for Diagnosis and Management, M. E. Eiler et al.,
Ed., pp. 33–48, Fanconi Anemia Research Fund, Eugene, Ore,
USA, 2008.
[33] M. Castella, R. Pujol, E. Callen et al., “Origin, functional role,
and clinical impact of Fanconi anemia FANCA mutations,”
Blood, vol. 117, no. 14, pp. 3759–3769, 2011.
[34] N. Ameziane, A. Errami, F. Le´veille´ et al., “Genetic subtyping
of Fanconi anemia by comprehensive mutation screening,”
Human Mutation, vol. 29, no. 1, pp. 159–166, 2008.
[35] J. R. Lo Ten Foe, M. T. Barel, P. Thuß, M. Digweed, F.
Arwert, and H. Joenje, “Sequence variations in the Fanconi
anaemia gene, FAC: pathogenicity of 1806insA and R548X
and recognition of D195V as a polymorphic variant,” Human
Genetics, vol. 98, no. 5, pp. 522–523, 1996.
[36] H. Hanenberg, S. D. Batish, K. E. Pollok et al., “Phenotypic
correction of primary Fanconi anemia T cells with retroviral
vectors as a diagnostic tool,” Experimental Hematology, vol. 30,
no. 5, pp. 410–420, 2002.
[37] S. Chandra, O. Levran, I. Jurickova et al., “A rapid method
for retrovirus-mediated identification of complementation
groups in Fanconi anemia patients,” Molecular Therapy, vol.
12, no. 5, pp. 976–984, 2005.
[38] T. N. Kaiser, A. Lojewski, C. Dougherty, L. Juergens, E.
Sahar, and S. A. Latt, “Flow cytometric characterization of the
response of Fanconi’s anemia cells to mitomycin C treatment,”
Cytometry, vol. 2, no. 5, pp. 291–297, 1982.
[39] F. O. Pinto, T. Leblanc, D. Chamousset et al., “Diagnosis
of Fanconi anemia in patients with bone marrow failure,”
Haematologica, vol. 94, no. 4, pp. 487–495, 2009.
[40] B. Hirsch, A. Shimamura, L. Moreau et al., “Association
of biallelic BRCA2/FANCD1 mutations with spontaneous
chromosomal instability and solid tumors of childhood,”
Blood, vol. 103, no. 7, pp. 2554–2559, 2004.
[41] J. E. Wagner, J. Tolar, O. Levran et al., “Germline mutations
in BRCA2: shared genetic susceptibility to breast cancer, early
onset leukemia, and Fanconi anemia,” Blood, vol. 103, no. 8,
pp. 3226–3229, 2004.
[42] K. Oﬃt, O. Levran, B. Mullaney et al., “Shared genetic
susceptibility to breast cancer, brain tumors, and Fanconi
anemia,” Journal of the National Cancer Institute, vol. 95, no.
20, pp. 1548–1551, 2003.
[43] S. Reid, D. Schindler, H. Hanenberg et al., “Biallelic mutations
in PALB2 cause Fanconi anemia subtype FA-N and predispose
to childhood cancer,” Nature Genetics, vol. 39, no. 2, pp. 162–
164, 2007.
[44] B. Xia, J. C. Dorsman, N. Ameziane et al., “Fanconi anemia is
associated with a defect in the BRCA2 partner PALB2,” Nature
Genetics, vol. 39, no. 2, pp. 159–161, 2007.
[45] K. Somyajit, S. Subramanya, and G. Nagaraju, “RAD51C: a
novel cancer susceptibility gene is linked to Fanconi anemia
and breast cancer,” Carcinogenesis, vol. 31, no. 12, pp. 2031–
2038, 2010.
[46] J. P. Schouten, C. J. McElgunn, R. Waaijer, D. Zwijnenburg,
F. Diepvens, and G. Pals, “Relative quantification of 40
nucleic acid sequences by multiplex ligation-dependent probe
amplification,” Nucleic acids research, vol. 30, no. 12, p. e57,
2002.
[47] A. R. Gennery, M. A. Slatter, A. Bhattacharya et al., “The
clinical and biological overlap between Nijmegen Breakage
syndrome and Fanconi anemia,” Clinical Immunology, vol.
113, no. 2, pp. 214–219, 2004.
[48] P. van der Lelij, A. B. Oostra, M. A. Rooimans, H. Joenje, and
J. P. de Winter, “Diagnostic overlap between Fanconi anemia
and the cohesinopathies: roberts syndrome and Warsaw
Breakage syndrome,” Anemia, vol. 2010, Article ID 565268, 7
pages, 2010.
[49] J. R. Lo Ten Foe, M. L. Kwee, M. A. Rooimans et al., “Somatic
mosaicism in Fanconi anemia: molecular basis and clinical
significance,” European Journal of Human Genetics, vol. 5, no.
3, pp. 137–148, 1997.
Anemia 13
[50] Q. Waisfisz, N. V. Morgan, M. Savino et al., “Spontaneous
functional correction of homozygous Fanconi anaemia alleles
reveals novel mechanistic basis for reverse mosaicism,” Nature
Genetics, vol. 22, no. 4, pp. 379–383, 1999.
[51] B. P. Alter, H. Joenje, A. B. Oostra, and G. Pals, “Fanconi
anemia: adult head and neck cancer and hematopoietic
mosaicism,” Archives of Otolaryngology, vol. 131, no. 7, pp.
635–639, 2005.
[52] A. L.Medhurst, E. H. Laghmani, J. Steltenpool et al., “Evidence
for subcomplexes in the Fanconi anemia pathway,” Blood, vol.
108, no. 6, pp. 2072–2080, 2006.
[53] B. P. Alter, C. L. Frissora, D. S. Halperin et al., “Fanconi’s
anaemia and pregnancy,” British Journal of Haematology, vol.
77, no. 3, pp. 410–418, 1991.
[54] P. S. Rosenberg, H. Tamary, and B. P. Alter, “How high are car-
rier frequencies of rare recessive syndromes? Contemporary
estimates for Fanconi anemia in the United States and Israel,”
American Journal of Medical Genetics A, vol. 155, no. 8, pp.
1877–1883, 2011.
[55] A. D. Auerbach, “Fanconi anemia,” inDiagnosis and Treatment
of the Unborn Child, M. I. New, Ed., pp. 27–35, Idelson-
Gnocchi, Naples, Italy, 1999.
[56] A. Bechtold, R. Kalb, K. Neveling et al., “Prenatal diagnosis
of Fanconi anemia: functional and molecular testing,” in
Fanconi Anemia. A Paradigmatic Disease for the Understanding
of Cancer and Aging, D. Schindler and H. Hoehn, Eds.,
Monographs in Human Genetics, pp. 131–148, Karger, Basel,
Switzerland, 2007.
[57] A. Merrill, L. Rosenblum-Vos, D. A. Driscoll, K. Daley, and
K. Treat, “Prenatal diagnosis of Fanconi anemia (Group
C) subsequent to abnormal sonographic findings,” Prenatal
Diagnosis, vol. 25, no. 1, pp. 20–22, 2005.
[58] D. I. Kutler, B. Singh, J. Satagopan et al., “A 20-year perspective
on the International Fanconi Anemia Registry (IFAR),” Blood,
vol. 101, no. 4, pp. 1249–1256, 2003.
[59] P. C. Verlander, A. Kaporis, Q. Liu, Q. Zhang, U. Seligsohn,
and A. D. Auerbach, “Carrier frequency of the IVS4 + 4 A—>
T mutation of the Fanconi anemia gene FAC in the Ashkenazi
Jewish population,” Blood, vol. 86, no. 11, pp. 4034–4038,
1995.
[60] M. Berwick, J. M. Satagopan, L. Ben-Porat et al., “Genetic
heterogeneity among Fanconi anemia heterozygotes and risk
of cancer,” Cancer Research, vol. 67, no. 19, pp. 9591–9596,
2007.
[61] M. Tischkowitz, D. F. Easton, J. Ball, S. V. Hodgson, and C.
G. Mathew, “Cancer incidence in relatives of British Fanconi
anaemia patients,” BMC Cancer, vol. 8, article 257, 2008.
[62] N. G. Howlett, T. Taniguchi, S. Olson et al., “Biallelic
inactivation of BRCA2 in Fanconi anemia,” Science, vol. 297,
no. 5581, pp. 606–609, 2002.
[63] E. Levy-Lahad and E. Friedman, “Cancer risks among BRCA1
and BRCA2 mutation carriers,” British Journal of Cancer, vol.
96, no. 1, pp. 11–15, 2007.
[64] N. Rahman, S. Seal, D. Thompson et al., “PALB2, which
encodes a BRCA2-interacting protein, is a breast cancer
susceptibility gene,” Nature Genetics, vol. 39, no. 2, pp. 165–
167, 2007.
[65] M. J. Garcia, V. Fernandez, A. Osorio et al., “Analysis
of FANCB and FANCN/PALB2 Fanconi anemia genes in
BRCA1/2-negative Spanish breast cancer families,” Breast
Cancer Research and Treatment, vol. 113, no. 3, pp. 545–551,
2009.
[66] A.Meindl, H. Hellebrand, C.Wiek et al., “Germline mutations
in breast and ovarian cancer pedigrees establish RAD51C as
a human cancer susceptibility gene,” Nature Genetics, vol. 42,
no. 5, pp. 410–414, 2010.
[67] A. R. Meetei, M. Levitus, Y. Xue et al., “X-linked inheritance of
Fanconi anemia complementation group B,” Nature Genetics,
vol. 36, no. 11, pp. 1219–1224, 2004.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
 Computational and  
Mathematical Methods 
in Medicine
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
